These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 7606724)

  • 1. Disposition and metabolism of the angiogenic moderator O-(chloroacetyl-carbamoyl) fumagillol (TNP-470; AGM-1470) in human hepatocytes and tissue microsomes.
    Placidi L; Cretton-Scott E; de Sousa G; Rahmani R; Placidi M; Sommadossi JP
    Cancer Res; 1995 Jul; 55(14):3036-42. PubMed ID: 7606724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interspecies variability of TNP-470 metabolism, using primary monkey, rat, and dog cultured hepatocytes.
    Placidi L; Scott EC; de Sousa G; Rahmani R; Placidi M; Sommadossi JP
    Drug Metab Dispos; 1997 Jan; 25(1):94-9. PubMed ID: 9010635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic drug interactions between angiogenic inhibitor, TNP-470 and anticancer agents in primary cultured hepatocytes and microsomes.
    Placidi L; Scott EC; Eckoff D; Bynon S; Sommadossi JP
    Drug Metab Dispos; 1999 May; 27(5):623-6. PubMed ID: 10220492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and metabolism of O-(chloroacetyl-carbamoyl) fumagillol (TNP-470, AGM-1470) in rhesus monkeys.
    Cretton-Scott E; Placidi L; McClure H; Anderson DC; Sommadossi JP
    Cancer Chemother Pharmacol; 1996; 38(2):117-22. PubMed ID: 8616900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolism of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) by murine and human hepatic preparations.
    Egorin MJ; Rosen DM; Wolff JH; Callery PS; Musser SM; Eiseman JL
    Cancer Res; 1998 Jun; 58(11):2385-96. PubMed ID: 9622079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of tumor growth and metastasis of rodent tumors by the angiogenesis inhibitor O-(chloroacetyl-carbamoyl)fumagillol (TNP-470; AGM-1470).
    Yamaoka M; Yamamoto T; Masaki T; Ikeyama S; Sudo K; Fujita T
    Cancer Res; 1993 Sep; 53(18):4262-7. PubMed ID: 7689930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamic-mediated reduction of temozolomide tumor concentrations by the angiogenesis inhibitor TNP-470.
    Ma J; Pulfer S; Li S; Chu J; Reed K; Gallo JM
    Cancer Res; 2001 Jul; 61(14):5491-8. PubMed ID: 11454697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I dose escalation pharmacokinetics of O-(chloroacetylcarbamoyl) fumagillol (TNP-470) and its metabolites in AIDS patients with Kaposi's sarcoma.
    Moore JD; Dezube BJ; Gill P; Zhou XJ; Acosta EP; Sommadossi JP
    Cancer Chemother Pharmacol; 2000; 46(3):173-9. PubMed ID: 11021733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced suppression of tumor growth by combination of angiogenesis inhibitor O-(chloroacetyl-carbamoyl)fumagillol (TNP-470) and cytotoxic agents in mice.
    Kato T; Sato K; Kakinuma H; Matsuda Y
    Cancer Res; 1994 Oct; 54(19):5143-7. PubMed ID: 7522956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiogenesis inhibitor TNP-470 (AGM-1470) potently inhibits the tumor growth of hormone-independent human breast and prostate carcinoma cell lines.
    Yamaoka M; Yamamoto T; Ikeyama S; Sudo K; Fujita T
    Cancer Res; 1993 Nov; 53(21):5233-6. PubMed ID: 7693335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Catabolism of 3'-azido-3'-deoxythymidine in hepatocytes and liver microsomes, with evidence of formation of 3'-amino-3'-deoxythymidine, a highly toxic catabolite for human bone marrow cells.
    Cretton EM; Xie MY; Bevan RJ; Goudgaon NM; Schinazi RF; Sommadossi JP
    Mol Pharmacol; 1991 Feb; 39(2):258-66. PubMed ID: 1996084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic efficacy of the angiogenesis inhibitor O-(chloroacetyl-carbamoyl) fumagillol (TNP-470; AGM-1470) for human anaplastic thyroid carcinoma in nude mice.
    Hama Y; Shimizu T; Hosaka S; Sugenoya A; Usuda N
    Exp Toxicol Pathol; 1997 Aug; 49(3-4):239-47. PubMed ID: 9314059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimizing the dosing schedule of TNP-470 [O-(chloroacetyl-carbamoyl) fumagillol] enhances its antitumor and antiangiogenic efficacies.
    Koyanagi S; Nakagawa H; Kuramoto Y; Ohdo S; Soeda S; Shimeno H
    J Pharmacol Exp Ther; 2003 Feb; 304(2):669-74. PubMed ID: 12538820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Phase I and pharmacokinetic study of TNP-470 administered weekly to patients with advanced cancer.
    Bhargava P; Marshall JL; Rizvi N; Dahut W; Yoe J; Figuera M; Phipps K; Ong VS; Kato A; Hawkins MJ
    Clin Cancer Res; 1999 Aug; 5(8):1989-95. PubMed ID: 10473076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assay of TNP-470 and its two major metabolites in human plasma by high-performance liquid chromatography-mass spectrometry.
    Whalen CT; Hanson GD; Putzer KJ; Mayer MD; Mulford DJ
    J Chromatogr Sci; 2002 Apr; 40(4):214-8. PubMed ID: 12004941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor effects of angiogenesis inhibitor 0-(chloroacetyl-carbamoyl) fumagillol (TNP-470) against murine renal cell carcinoma.
    Fujioka T; Hasegawa M; Ogiu K; Matsushita Y; Sato M; Kubo T
    J Urol; 1996 May; 155(5):1775-8. PubMed ID: 8627882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro metabolism of rivaroxaban, an oral, direct factor Xa inhibitor, in liver microsomes and hepatocytes of rats, dogs, and humans.
    Lang D; Freudenberger C; Weinz C
    Drug Metab Dispos; 2009 May; 37(5):1046-55. PubMed ID: 19196846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NTP technical report on the toxicity and metabolism studies of chloral hydrate (CAS No. 302-17-0). Administered by gavage to F344/N rats and B6C3F1 mice.
    Beland FA
    Toxic Rep Ser; 1999 Aug; (59):1-66, A1-E7. PubMed ID: 11803702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plausible novel therapeutic strategy of uterine endometrial cancer with reduction of basic fibroblast growth factor secretion by progestin and O-(chloroacetyl-carbamoyl) fumagillol (TNP-470; AGM-1470).
    Fujimoto J; Hori M; Ichigo S; Hirose R; Sakaguchi H; Tamaya T
    Cancer Lett; 1997 Feb; 113(1-2):187-94. PubMed ID: 9065821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro metabolism of the HIV-1 protease inhibitor ABT-378: species comparison and metabolite identification.
    Kumar GN; Jayanti V; Lee RD; Whittern DN; Uchic J; Thomas S; Johnson P; Grabowski B; Sham H; Betebenner D; Kempf DJ; Denissen JF
    Drug Metab Dispos; 1999 Jan; 27(1):86-91. PubMed ID: 9884314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.